Osteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance

Size: px
Start display at page:

Download "Osteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance"

Transcription

1 Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline of 15

2 This costing report accompanies the clinical guideline: Osteoporosis: assessing the risk of fragility fracture'](available online at Issue date: August 2012 This guidance is written in the following context This report represents the view of NICE, which was arrived at after careful consideration of the available data and through consulting with healthcare professionals. It should be read in conjunction with the NICE guideline. The report is an implementation tool and focuses on the recommendations that were considered to have a significant impact on national resource utilisation. Assumptions used in the report are based on assessment of the national average. Local practice may be different from this, and the impact should be estimated locally. Implementation of the guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement this guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in the costing assessment should be interpreted in a way that would be inconsistent with compliance with those duties National Institute for Health and Clinical Excellence Level 1A City Tower Piccadilly Plaza Manchester M1 4BT National Institute for Health and Clinical Excellence (2012). All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE. 2 of 15

3 Contents Executive summary... 4 Potential resource-impact recommendations... 4 Costs... 4 Benefits and savings Introduction Supporting implementation What is the aim of this report? Epidemiology of osteoporosis Current service provision Costing methodology Process Scope of the cost-impact analysis Analysis of the potential resource impact Targeting risk assessment Methods of risk assessment Impact of guidance for commissioners Osteoporotic fractures - denosumab (TA204) Conclusion Appendix A. Approach to costing guidelines of 15

4 Executive summary This costing report looks at the resource impact of implementing the NICE guideline Osteoporosis: assessing the risk of fragility fracture (available online at in England. The costing method adopted is outlined in appendix A; it uses the most accurate data available, was produced in conjunction with key clinicians, and reviewed by clinical and financial professionals. Potential resource-impact recommendations This report focuses on the recommendations that are likely to have the greatest resource impact and therefore require the most additional resources to implement or can potentially generate the biggest savings. They are: Targeting risk assessment (recommendation 1.1) Methods of risk assessment (recommendation 1.7) This report discusses the potential costs and savings that need to be considered at a local level. Because of the variation in current practice and insufficient data a national resource impact is not provided. This report discusses the potential costs and savings that need to be considered at a local level. A local costing template has been developed to help organisations calculate the local resource impact Overall the Guideline development group (GDG) indicated that this guidance may reduce costs to the NHS due to the potential reduction in the number of DXA 1 scans performed. Costs A national estimate of costs or savings of implementing the guideline is not provided due to the degree of uncertainty. 1 DXA (or DEXA) stands for Dual Energy X-ray Absorptiometry. A DXA scan (also known as bone density scans or bone densitometry scans) is a type of X-ray that measures bone density. They are most commonly used to diagnose osteoporosis, but can also be used to assess the risk of osteoporosis developing. 4 of 15

5 It is anticipated that there may be an increase in costs associated with an increase in the number of fragility fracture risk assessments carried out, mainly in relation to extra clinical time needed to perform the assessments. However, it is anticipated that many of these extra risk assessments could be undertaken opportunistically, as part of a consultation with a healthcare professional that the person is attending for other reasons, which would reduce the cost impact of the recommendations. Benefits and savings Implementing the clinical guideline may result in savings and benefits associated with more appropriate use of dual-energy X-ray absorptiometry (DXA) scans, because the use of DXA should be directed at those most at risk of fragility fracture, identified by risk assessment tools. Osteoporotic fractures can cause substantial pain and severe disability, often leading to reduced quality of life, and hip and vertebral fractures are associated with decreased life expectancy. Hip fracture nearly always results in hospitalisation, is fatal in 20% of cases and permanently disables 50% of those affected; only 30% of people fully recover. Therefore, strategies which reduce the number of osteoporotic fractures should improve quality of life for people with osteoporosis and reduce costs associated with treating these fractures. 1 Introduction 1.1 Supporting implementation The NICE clinical guideline on osteoporosis fragility fracture risk is supported by the following implementation tools available on our website: costing tools a national costing report; this document a local costing template; a simple spreadsheet that can be used to estimate the local cost of implementation 5 of 15

6 baseline assessment tool; assess your baseline against the recommendations in the guidance in order to prioritise implementation activity, including clinical audit a package of audit support. 1.2 What is the aim of this report? This report aims to help organisations assess and plan for the financial implications of implementing NICE guidance This report does not reproduce the NICE guideline on osteoporosis fragility fracture risk and should be read in conjunction with it The costing template that accompanies this report is designed to help those assessing the resource impact at a local level in England, Wales or Northern Ireland 1.3 Epidemiology of osteoporosis The British Orthopaedic Association estimates that in the UK over 300,000 people present to hospital with fragility fractures every year. Around a quarter of these fractures are hip fractures The National Osteoporosis Society estimates that there are 2.3 million people in England with osteoporosis and that over 1100 deaths in the UK every month are a result of hip fracture The National Osteoporosis Society estimates that 1 in 2 women and 1 in 5 men aged over 50 in the UK will break a bone because of poor bone health Direct medical costs to the UK healthcare economy from fragility fractures have been estimated at 2.3 billion in 2011, with the potential to increase to more than 6 billion by Most of these costs relate to hip fracture care. 6 of 15

7 1.4 Current service provision The aim of identifying people at risk is to offer preventive treatment. There are many treatments available for preventing fragility fractures but it is difficult to identify who will benefit from them A number of risk assessment tools are available to predict risk of fracture, including: the fracture risk assessment tool (FRAX); QFracture; Women's Health Initiative (WHI) hip fracture risk calculator; and Foundation for Osteoporosis Research and Education (FORE) 10-year fracture risk calculator. The guideline recommends the use of FRAX and QFracture In 2012/13, three new indicators relating to secondary prevention of fragility fractures (OST1, 2 and 3) were added to the Quality Outcomes Framework (QOF) Expert opinion suggests that targeted risk assessment is not routine practice in primary care. It is therefore anticipated that the guidance recommendations will have an impact on primary care time needed to carry out the risk assessment. 2 Costing methodology 2.1 Process We use a structured approach for costing clinical guidelines (see appendix A) We have to make assumptions in the costing model. These are tested for reasonableness with members of the Guideline Development Group (GDG) and key clinical practitioners in the NHS. 2.2 Scope of the cost-impact analysis The guideline offers best practice advice on osteoporosis fragility fracture risk. 7 of 15

8 2.2.2 The guidance does not cover children and young people (younger than 18), drugs to prevent fractures or fractures and post-fracture management. Therefore, these issues are outside the scope of the costing work Rather than cost each individual recommendation, costing work has focused on the areas that will potentially need the most resources to implement or generate the biggest savings. These areas were determined in discussion with the clinical guideline project team and the members of the GDG Of the 12 recommendations in the guideline, 2 were identified as having the greatest resource impact. 3 Analysis of the potential resource impact 3.1 Targeting risk assessment Recommendations Consider assessment of fracture risk in: all women aged 65 years and over and men aged 75 years and over women aged under 65 years and men aged under 75 years who have risk factors, for example: previous fragility fracture current use or frequent recent use of oral or systemic glucocorticoids history of falls family history of hip fracture other causes of secondary osteoporosis 2 2 Causes of secondary osteoporosis include endocrine (hypogonadism in either sex including untreated premature menopause and treatment with aromatase inhibitors or androgen deprivation therapy; hyperthyroidism; hyperparathyroidism; hyperprolactinaemia; Cushing s disease; diabetes), gastrointestinal (coeliac disease; inflammatory bowel disease; chronic liver disease; chronic pancreatitis; other causes of malabsorption), rheumatological 8 of 15

9 low body mass index (BMI) (less than 18.5 kg/m 2 ) smoking alcohol intake of more than 14 units per week for women and more than 21 units per week for men (recommendation 1.1). Potential cost impact Expert opinion suggests that it is not current practice to perform risk assessment for people defined in paragraph 3.1.1, therefore it is anticipated that these recommendations would affect primary care time needed to carry out the risk assessment A calculation of the number of men aged under 75 and women aged under 65 who smoke, shows that approximately 4.2 million males and 3.5 million females could be considered for assessment of fracture risk on the basis of their smoking. (NHS Information centre, Statistics on Smoking, England 2011) A calculation of the number of men aged under 75 with alcohol intake of more than 21 units per week and the number of women aged under 65 with alcohol intake of more than 14 units per week, shows that approximately 4.8 million men and 3.2 million women could be considered for assessment of fracture risk on the basis of their alcohol intake (ONS Statistics on Alcohol, England Table 2.4) The GDG estimated that an additional 10 minutes of time would be needed to perform a FRAX or QFracture risk assessment. The GDG acknowledged that this may be an overestimate. The length of time needed for a GP consultation may be longer or shorter than 10 minutes, depending upon the outcome of the FRAX or QFracture risk assessment. (rheumatoid arthritis; other inflammatory arthropathies), haematological (multiple myeloma; haemoglobinopathies; systemic mastocytosis), respiratory (cystic fibrosis; chronic obstructive pulmonary disease), metabolic (homocystinuria), chronic renal disease and immobility (due, for example, to neurological injury or disease). 9 of 15

10 3.1.6 It is estimated that 81% of men and 86% of women aged 65 years and over would visit their general practice in the first year. Therefore the majority of people eligible for assessment under recommendation 1.1 could be assessed opportunistically, as part of a consultation with a healthcare professional that the person is attending for other reasons. This would reduce the cost of assessing this group of people, because the time taken to perform the assessment would be part of the existing attendance There are no costs to use the FRAX and QFracture risk assessment tools. The GDG considered that the time to undertake either assessment would be the same The cost of a GP consultation is for a surgery consultation lasting 11.7 minutes. However, the risk assessment could be carried out by other suitably qualified healthcare professionals, for example, practice nurses. This would reduce the cost of a consultation; for example, the cost of a consultation with a practice nurse is per hour, so a 10-minute consultation would cost 8.50 (Curtis 2011) The cost impact of this recommendation is dependent on current local practice The cost of a DXA scan payable by commissioners is The latest available reference costs for a DXA scan incurred by providers in 2010/11 is (Department of Health, National Tariff ) Therefore the maximum additional cost per person is the cost of a GP consultation plus the cost of a DXA scan. (This would decrease to if the risk assessment was performed by a practice nurse, as detailed in section 3.1.7, and would be reduced further if the assessment could be undertaken on an opportunistic basis). 10 of 15

11 Although prevention and treatment are outside the scope of the guideline, there may be considerable benefits associated with the use of a risk assessment tool that facilitates early intervention and prevention of fragility fracture. 3.2 Methods of risk assessment Recommendation Following risk assessment with FRAX (without a bone mineral density (BMD) value) or QFracture, consider measuring BMD with DXA in people whose fracture risk is in the region of an intervention threshold 3 for a proposed treatment, and recalculate absolute risk using FRAX with the BMD value (recommendation 1.7). Potential cost impact Expert opinion suggests that recommendation 1.7 may lead to a reduction in the number of DXA scans in the general population because DXA would be used for people identified, using risk assessment tools, as being most at risk of fragility fracture It is not possible to estimate the potential resource impact nationally because of the difficulty in identifying the number of scans that would be avoided. For each DXA scan avoided there is a potential saving of Organisations are encouraged to review local practice and estimate savings locally. 4 Impact of guidance for commissioners The cost of a DXA scan is included in the Payment by Results national tariff. The costs of GP and practice nurse consultation time are not included in the national tariff. 3 An intervention threshold is the level of risk at which an intervention is recommended. People whose risk is in the region from just below to just above the threshold may be reclassified if BMD is added to assessment. It is out of the scope of this guideline to recommend intervention thresholds. Healthcare professionals should follow local protocols or other national guidelines for advice on intervention thresholds. 11 of 15

12 4.1.2 Costs fall under programme budgeting code 15: problems of the musculoskeletal system The 2012/13 Quality and Outcomes Framework (QOF) introduced 3 new indicators (OST1, 2 and 3) that record the number of people aged 50 and older with a fragility fracture who are being treated with an appropriate bone-sparing agent. The aim of the QOF indicators is to support high-quality, cost-effective patient care. It is likely that the introduction of these indicators may lead to an increase in osteoporosis diagnoses. The inclusion of these indicators in the QOF supports the implementation of this guidance as assessment of fracture risk is to be considered in women aged under 65 years and men aged under 75 years who have risk factors including previous fragility fracture Commissioners need to develop procedures for risk assessment, for example, whether this should be undertaken by GPs or another appropriate healthcare professional such as a practice nurse Whilst the treatment of osteoporosis is outside the scope of this guideline NICE has published a number of technology appraisals which commissioners may wish to refer to as follows -: Osteoporosis-primary prevention-ta160 Osteoporosis-secondary prevention-ta161 Osteoporotic fractures - denosumab (TA204) 5 Conclusion This guideline covers the selection and use of risk assessment tools in the care of people who may be at risk of fragility fractures in all settings in which NHS care is received. It is not possible to calculate the national resource impact of the recommendations. However the costing template that accompanies this report is 12 of 15

13 designed to help those assessing the resource impact at a local level in England, Wales or Northern Ireland NHS organisations and local authorities are advised to assess local resource implications, and the level of costs or savings that may be expected in their area Although it is not possible to calculate the national resource impact of this guideline, the GDG considers that implementation would lead to an overall reduction in the number of DXA scans performed. 13 of 15

14 Appendix A. Approach to costing guidelines Guideline at first consultation stage Analyse the clinical pathway to identify significant recommendations and population cohorts affected Identify key cost drivers gather information needed and research cost behaviour Develop costing report Internal peer review by qualified accountant within NICE Circulate report to cost impact panel and GDG for comments Update based on feedback and any changes following consultation Cost-impact review meeting Final sign-off by NICE Prepare for publication in conjunction with guideline 14 of 15

15 Appendix B. References British Orthopaedic Association (2007) The care of patients with fragility fracture Curtis L (2011) Unit costs of health and social care Canterbury: University of Kent Personal Social Services Research Unit. Department of Health Payment by Results, National tariff National Osteoporosis Society Osteoporosis facts and figures version 1.1. NICE clinical guideline 146 Osteoporosis fragility fracture risk NICE public health guidance 24 Alcohol-use disorders preventing harmful drinking: costing report. ONS Statistics on Alcohol, England 2011 Table 2.4. NHS Information centre, Statistics on Smoking, England 2011 Table of 15

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: : assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new

More information

Case Finding and Risk Assessment for Osteoporosis

Case Finding and Risk Assessment for Osteoporosis Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors

More information

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:

More information

Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)

Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical

More information

Osteoporosis: assessing the risk of fragility fracture

Osteoporosis: assessing the risk of fragility fracture Osteoporosis: assessing the risk of fragility fracture Issued: August 2012 NICE clinical guideline 146 guidance.nice.org.uk/cg146 NICE has accredited the process used by the Centre for Clinical Practice

More information

Costing tool: Osteoarthritis Implementing the NICE guideline on osteoarthritis (CG177)

Costing tool: Osteoarthritis Implementing the NICE guideline on osteoarthritis (CG177) Putting NICE guidance into practice Costing tool: Osteoarthritis Implementing the NICE guideline on osteoarthritis (CG177) Published: February 2014 This costing report accompanies the clinical guideline

More information

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper Quality standard topic: Osteoporosis Output: Prioritised quality improvement

More information

Costing report: Bladder cancer

Costing report: Bladder cancer Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral

More information

nice bulletin NICE provided the content for this booklet which is independent of any company or product advertised

nice bulletin NICE provided the content for this booklet which is independent of any company or product advertised nice bulletin NICE provided the content for this booklet which is independent of any company or product advertised nice bulletin Welcome In August 2012, the National Institute for Health and Clinical Excellence

More information

SCHEDULE 2 THE SERVICES. A. Service Specifications

SCHEDULE 2 THE SERVICES. A. Service Specifications SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy

More information

Quality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture

Quality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged

More information

Putting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)

Putting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98) Putting NICE guidance into practice Resource impact report: Hearing loss in adults: assessment and management (NG98) Published: June 2018 Summary This report focuses on the recommendation from NICE s guideline

More information

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

DEXA SCAN POLICY CRITERIA BASED ACCESS

DEXA SCAN POLICY CRITERIA BASED ACCESS DEXA SCAN POLICY Version: 1718.v2 Recommendation by: Somerset CCG Clinical Commissioning Policy Forum (CCPF) Date Ratified: 01 November 2017 Name of Originator/Author: Approved by Responsible Committee/Individual:

More information

Extracorporeal shockwave therapy for refractory Achilles tendinopathy

Extracorporeal shockwave therapy for refractory Achilles tendinopathy Extracorporeal shockwave therapy for refractory Achilles Issued: August 2009 www.nice.org.uk/ipg312 NHS Evidence has accredited the process used by the NICE Interventional Procedures Programme to produce

More information

Costing report: Erythropoiesisstimulating

Costing report: Erythropoiesisstimulating Putting NICE guidance into practice Costing report: Erythropoiesisstimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer receiving chemotherapy (including review of TA142)

More information

Putting NICE guidance into practice

Putting NICE guidance into practice Putting NICE guidance into practice Resource impact report: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after

More information

Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis

Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis Issued: August 2007 www.nice.org.uk/ipg230 Copyright NICE 2007 Contents 1 Guidance... 3 2 The procedure... 4

More information

Putting NICE guidance into practice

Putting NICE guidance into practice Putting NICE guidance into practice Costing statement Implementing the NICE guidance on Oral health: approaches for local authorities and their partners to improve the oral health of their communities

More information

Infracoccygeal sacropexy using mesh for uterine prolapse repair

Infracoccygeal sacropexy using mesh for uterine prolapse repair Infracoccygeal sacropexy using mesh for uterine Issued: January 2009 www.nice.org.uk/ipg280 NHS Evidence has accredited the process used by the NICE Interventional Procedures Programme to produce interventional

More information

FRAX, NICE and NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

FRAX, NICE and NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield FRAX, NICE and NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Research funding and/or honoraria and/or advisory boards for: o ActiveSignal, Amgen, Bayer, Boehringer

More information

IMPROVING BONE HEALTH AND FRACTURE PREVENTION

IMPROVING BONE HEALTH AND FRACTURE PREVENTION IMPROVING BONE HEALTH AND FRACTURE PREVENTION Helen Ridley, Programme Lead, North East & North Cumbria Academic Health Science Network NORTH EAST REGION 2014/15 AHSN Single Sponsored Project Hadrian Primary

More information

NICE support for commissioning for urinary tract infection in infants, children and young people under 16

NICE support for commissioning for urinary tract infection in infants, children and young people under 16 NICE support for commissioning for urinary tract infection in infants, children and young people under 16 July 2013 1 Introduction Implementing the recommendations from NICE guidance and other NICEaccredited

More information

Understanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.

Understanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS. Understanding NICE guidance Information for people who use NHS services Alendronate, etidronate, risedronate, strontium ranelate and raloxifene for preventing bone fractures in postmenopausal women with

More information

Implanting pressure monitors in the pulmonary artery to monitor chronic heart failure

Implanting pressure monitors in the pulmonary artery to monitor chronic heart failure Issue date August 2013 Information for the public Implanting pressure monitors in the pulmonary artery to monitor chronic heart failure NICE interventional procedures guidance advises the NHS on when and

More information

An audit of osteoporotic patients in an Australian general practice

An audit of osteoporotic patients in an Australian general practice professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to

More information

Putting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80)

Putting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80) Putting NICE guidance into practice Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80) Published: November 2017 Summary This report focuses on the recommendations

More information

Osteoporosis challenges

Osteoporosis challenges Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1

More information

May Professor Matt Stevenson School of Health and Related Research, University of Sheffield

May Professor Matt Stevenson School of Health and Related Research, University of Sheffield ASSESSING THE FEASIBILITY OF TRANSFORMING THE RECOMMENDATIONS IN TA160, TA161 AND TA204 INTO ABSOLUTE 10-YEAR RISK OF FRACTURE A REPORT PRODUCED BY THE DECISION SUPPORT UNIT IN THE CONTEXT OF THE REVIEW

More information

Low back pain and sciatica in over 16s NICE quality standard

Low back pain and sciatica in over 16s NICE quality standard March 2017 Low back pain and sciatica in over 16s NICE quality standard Draft for consultation This quality standard covers the assessment and management of non-specific low back pain and sciatica in young

More information

Smoking cessation interventions and services

Smoking cessation interventions and services National Institute for Health and Care Excellence Guideline version (Final) Smoking cessation interventions and services [E] Evidence reviews for advice NICE guideline NG92 Evidence reviews FINAL These

More information

Incisionless surgery to correct protruding ears

Incisionless surgery to correct protruding ears Issue date March 2012 Understanding NICE guidance Information for people who use NHS services Incisionless surgery to correct protruding ears NICE interventional procedures guidance advises the NHS on

More information

South East Coast Operational Delivery Network. Critical Care Rehabilitation

South East Coast Operational Delivery Network. Critical Care Rehabilitation South East Coast Operational Delivery Networks Hosted by Medway Foundation Trust South East Coast Operational Delivery Network Background Critical Care Rehabilitation The optimisation of recovery from

More information

Haemorrhoidal artery ligation

Haemorrhoidal artery ligation Haemorrhoidal artery ligation Issued: May 2010 NICE interventional procedure guidance 342 www.nice.org.uk/ipg342 NHS Evidence has accredited the process used by the NICE Interventional Procedures Programme

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis

More information

Validation of QFracture. Analysis prepared for NICE 2011

Validation of QFracture. Analysis prepared for NICE 2011 Validation of QFracture compared with FRAX Analysis prepared for NICE 2011 Authors: Julia Hippisley-Cox & Carol Coupland Email: Julia.hippisley-cox@nottingham.ac.uk Julia Hipisley-Cox, University of Nottingham,

More information

Case scenarios: Patient Group Directions

Case scenarios: Patient Group Directions Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios

More information

Using the FRAX Tool. Osteoporosis Definition

Using the FRAX Tool. Osteoporosis Definition How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX

More information

Resource impact report: Eating disorders: recognition and treatment (NG69)

Resource impact report: Eating disorders: recognition and treatment (NG69) Resource impact report: Eating disorders: recognition and treatment (NG69) Published: May 2017 Summary This report looks at the resource impact of implementing NICE s guideline on eating disorders: recognition

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Diabetes dietary review Potential output: Recommendations

More information

Osteoporosis: fragility fracture risk

Osteoporosis: fragility fracture risk Fragility fracture risk Osteoporosis: fragility fracture risk Osteoporosis: assessing the risk of fragility fracture Short clinical guideline Evidence and recommendations January 0 Draft for consultation

More information

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Advanced medicine conference. Monday 20 Tuesday 21 June 2016 Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus

More information

Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures

Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations

More information

Osteoporosis Clinical Guideline. Rheumatology January 2017

Osteoporosis Clinical Guideline. Rheumatology January 2017 Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis

More information

Deep brain stimulation for difficultto-treat

Deep brain stimulation for difficultto-treat Issue date January 2012 Understanding NICE guidance Information for people who use NHS services Deep brain stimulation for difficultto-treat epilepsy NICE interventional procedures guidance advises the

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

NICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield NICE SCOOP OF THE DAY FRAX with NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Consultant/Advisor/Speaker for: o ActiveSignal, Amgen, AstraZeneca, Consilient

More information

Clinical Specialist Statement Template

Clinical Specialist Statement Template Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can

More information

Bisphosphonates for preventing osteoporotic fragility fracture

Bisphosphonates for preventing osteoporotic fragility fracture Bisphosphonates for preventing osteoporotic fragility fracture An example of a multi-dimensional modelling problem Sarah Davis, ScHARR Background Project was part of ongoing NICE Multiple Technology Appraisal

More information

Prostate artery embolisation for benign prostatic hyperplasia

Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic Issued: April 2013 guidance.nice.org.uk/ipg NICE has accredited the process used by the NICE Interventional Procedures Programme to produce interventional

More information

Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness

Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness of risedronate and strontium ranelate in those people who would be treated with generic

More information

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106 Issue date: September 2010 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Part review of NICE technology appraisal guidance 75 and 106 National Institute for Health and Clinical

More information

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance Epilepsy: pharmacological treatment by seizure type Clinical audit tool Implementing NICE guidance 2012 NICE clinical guideline 137 Clinical audit tool: Epilepsy (2012) Page 1 of 25 This clinical audit

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

Costing report. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Implementing NICE guidance.

Costing report. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Implementing NICE guidance. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension Costing report Implementing NICE guidance April 2009 NICE clinical guideline 85 National costing report: glaucoma

More information

Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families

Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families What the NHS should provide for people over 50 who have broken a bone after falling from standing height

More information

Audit on follow-up of patients with primary Osteoporosis

Audit on follow-up of patients with primary Osteoporosis Abstract Aim: To document the frequency of Dual-energy X- ray absorptiometry (DEXA) scanning and Rheumatology clinic follow-up visits of patients with primary osteoporosis, and compare these with recommended

More information

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Denosumab for the prevention of osteoporotic fractures in postmenopausal women Issue date: October 2010 Denosumab for the prevention of osteoporotic fractures in postmenopausal women This guidance was developed using the single technology appraisal process NICE technology appraisal

More information

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary

More information

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts

More information

BEST PRACTICE FRAMEWORK

BEST PRACTICE FRAMEWORK IOF CAPTURE the FRACTURE BEST PRACTICE FRAMEWORK for FRACTURE LIAISON SERVICES Setting the standard Studies have shown that Fracture Liaison Service models are the most cost-effective in preventing secondary

More information

Treating severe obesity using keyhole surgery to stitch folds in the stomach to make it smaller

Treating severe obesity using keyhole surgery to stitch folds in the stomach to make it smaller Issue date November 2012 Information for the public NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical practice. Treating severe obesity using

More information

Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families

Strong bones after 50 Fracture liaison services explained A guide for patients, carers and families What the NHS should provide for people over 50 who have broken a bone after falling from standing height or less. Feedback Strong bones after 50 A guide for patients, carers and families What the NHS should

More information

Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430

Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option

More information

QOF indicator area: Chronic Obstructive Pulmonary disease (COPD)

QOF indicator area: Chronic Obstructive Pulmonary disease (COPD) NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Chronic Obstructive Pulmonary Disease QOF indicator area:

More information

BEST PRACTICE FRAMEWORK QUESTIONNAIRE

BEST PRACTICE FRAMEWORK QUESTIONNAIRE CAPTURE the FRACTURE BEST PRACTICE FRAMEWORK QUESTIONNAIRE INTRODUCTION Capture the Fracture invites Fracture Liaison Services (FLS) to apply for Capture the Fracture Best Practice Recognition programme.

More information

RESEARCH. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

RESEARCH. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores Julia Hippisley-Cox, professor of clinical epidemiology and general

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Nutrition support in adults: oral supplements, enteral and parenteral feeding.

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Nutrition support in adults: oral supplements, enteral and parenteral feeding. NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Nutrition support in adults: oral supplements, enteral and parenteral feeding. 1.1 Short title Nutrition support 2 Background a) The National

More information

Competency Framework For Fracture Prevention Practitioners National Osteoporosis Society 2016

Competency Framework For Fracture Prevention Practitioners National Osteoporosis Society 2016 Competency Framework For Fracture Prevention Practitioners National Osteoporosis Society 2016 1 Introduction The National Osteoporosis Society is the only UK wide charity dedicated to improving the diagnosis,

More information

Review of bisphosphonate prescribing May 2014

Review of bisphosphonate prescribing May 2014 Title of Project: NHS Dumfries & Galloway Review of bisphosphonate prescribing May 2014 1 Reason for the review The aim of this audit is to review patients prescribed a bisphosphonate for the prophylaxis

More information

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide

More information

Medical technologies guidance Published: 2 October 2018 nice.org.uk/guidance/mtg39

Medical technologies guidance Published: 2 October 2018 nice.org.uk/guidance/mtg39 ifuse for treating chronic sacroiliac joint pain Medical technologies guidance Published: 2 October 2018 nice.org.uk/guidance/mtg39 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Submission to the National Institute for Clinical Excellence on

Submission to the National Institute for Clinical Excellence on Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology

More information

Clinical Appropriateness Guidelines: Advanced Imaging

Clinical Appropriateness Guidelines: Advanced Imaging Clinical Appropriateness Guidelines: Advanced Imaging Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry Effective Date: September 5, 2017 Proprietary Date of Origin: 05/21/2007

More information

Quality Standards for Osteoporosis and Prevention of Fragility Fractures

Quality Standards for Osteoporosis and Prevention of Fragility Fractures Draft for consultation Quality Standards for Osteoporosis and Prevention of Fragility Fractures September 0 Have your say We would welcome your views and opinions. Please use the consultation response

More information

Treating localised prostate cancer using freezing (cryotherapy) needles in a targeted area of the prostate

Treating localised prostate cancer using freezing (cryotherapy) needles in a targeted area of the prostate Issue date April 2012 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical

More information

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies

More information

Early Inflammatory Arthritis Pathway Rheumatology Service Commissioner Lead

Early Inflammatory Arthritis Pathway Rheumatology Service Commissioner Lead Schedule 2 Part A Service Specification Number 04/MSKT/0014 Care Pathway/Service Early Inflammatory Arthritis Pathway Rheumatology Service Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead

More information

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective

More information

Alcohol and Drug Commissioning Framework for Northern Ireland Consultation Questionnaire.

Alcohol and Drug Commissioning Framework for Northern Ireland Consultation Questionnaire. Alcohol and Drug Commissioning Framework for Northern Ireland 2013-16 Consultation Questionnaire. This questionnaire has been designed to help stakeholders respond to the above framework. Written responses

More information

Practical Management Of Osteoporosis

Practical Management Of Osteoporosis Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda

More information

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease Produced on behalf of NHS Wales and Welsh Government April 2018 Table of Contents Introduction... 3 Variation in health services...

More information

Bridging the gap between acute and community falls services

Bridging the gap between acute and community falls services Bridging the gap between acute and community falls services Melissa Turner Falls Therapy Link Worker Westminster Rehabilitation Services Melissa.Turner@clch.nhs.uk Providing community healthcare in London

More information

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

The audit is managed by the Royal College of Psychiatrists in partnership with:

The audit is managed by the Royal College of Psychiatrists in partnership with: Background The National Audit of Dementia (NAD) care in general hospitals is commissioned by the Healthcare Quality Improvement Partnership on behalf of NHS England and the Welsh Government, as part of

More information

Summary. Background. Diagnosis

Summary. Background. Diagnosis March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.

More information

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator QOF indicator area: Hypertension Over 80 Potential output:

More information

Aromatase Inhibitors & Osteoporosis

Aromatase Inhibitors & Osteoporosis Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health

More information

All about. Osteoporosis

All about. Osteoporosis All about Osteoporosis What is osteoporosis? Osteoporosis literally means porous bone. It is a condition that causes bones to become thin and fragile, decreasing bone strength and making them more prone

More information

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator QOF indicator area: Hypertension Under 80 Potential output:

More information

August 2009 Ceri J. Phillips and Andrew Bloodworth

August 2009 Ceri J. Phillips and Andrew Bloodworth Cost of smoking to the NHS in Wales August 2009 Ceri J. Phillips and Andrew Bloodworth Key Findings Smoking cost NHS Wales an estimated 386 million in 2007/08; equivalent to 129 per head and 7% of total

More information

Pathway from Fracture or Risk Factor to Treatment

Pathway from Fracture or Risk Factor to Treatment Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height

More information

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density

More information